Affiliation:
1. Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy
2. Center for the Study of Atherosclerosis, Bassini Hospital, 20092 Cinisello Balsamo, Italy
3. Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), 90-419 Lodz, Poland
Abstract
Red yeast rice (RYR) has a cholesterol-lowering effect due to the presence of bioactive components (monacolins, mainly monacolin K) that act by inhibiting the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. The European Food Safety Authority (EFSA) assessed the use of RYR and, while pointing out several uncertainties regarding the available data, raised a warning related to the safety of RYR when used as a food supplement at a dose of monacolin as low as 3 mg/day. In their decision in June 2023, EFSA approved the use of monacolins from RYR at doses less than 3 mg/day. We therefore decided to interrogate the different adverse event reporting systems (FAERS and CAERS) and analyse the characteristics of the cases reported to be associated with RYR supplements, and we reviewed the most recent meta-analyses with a focus on the occurrence of muscle symptoms and liver dysfunction. In terms of all musculoskeletal disorders from September 2013 (when the first case related to RYR consumption was recorded) to 30 September 2023, 363,879 cases were reported in the FAERS, with the number of cases related to RYR consumption being very small and accounting for 0.008% of cases. In the same time frame, 27,032 cases of hepatobiliary disorders were reported, and the cases attributable to RYR ingestion accounted for 0.01% of all cases. A low rate of muscle symptoms and liver dysfunction attributed to RYR ingestion was also observed in the CAERS database, where only 34 cases of adverse muscle events and 10 cases of adverse liver events reported RYR as the suspect product, while 19 cases of both muscle events and 10 cases of adverse liver events reported it as a concomitant product. This profile mirrors that of meta-analyses of randomised clinical trials of RYR, in which RYR use was not associated with either liver dysfunction or muscular adverse symptoms.
Funder
Progetti di Rilevante Interesse Nazionale
Ricerca Finalizzata, Ministry of Health
PNRR Missione 4, [Progetto CN3-National Center for Gene Therapy and Drugs based on RNA Technology]
PNRR Missione 4 [Progetto MUSA-Multilayered Urban Sustainability Action]
PNRR Missione 6
SISTE
European Commission
Reference19 articles.
1. Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar;Cicero;J. Am. Coll. Cardiol.,2021
2. Alternative lipid lowering strategies: State-of-the-art review of red yeast rice;Buzzelli;Fitoterapia,2024
3. The current trend and challenges of developing red yeast rice-based food supplements for hypercholesterolemia;Chen;J. Future Foods,2023
4. Impact of red yeast rice supplementation on lipid profile: A systematic review and meta-analysis of randomized-controlled trials;Rahmani;Expert Rev. Clin. Pharmacol.,2023
5. (2023, November 03). FDA Warns Consumers to Avoid Red Yeast Rice Products Promoted on Internet as Treatments for High Cholesterol, Available online: https://www.in.gov/health/food-protection/recalls-and-advisories/2007-advisories/red-yeast-rice-products/.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献